Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sahar Bannoura"'
Autor:
Husain Yar Khan, PhD, Mandana Kamgar, MD, Amro Aboukameel, MS, Sahar Bannoura, MS, Brian Y. Chung, PhD, Yiwei Li, MD, Mohammed Najeeb Al Hallak, MD, Philip A. Philip, MD, PhD, Susan Tsai, MD, Sanjeev Luther, MBA, William A. Hall, MD, Asfar S. Azmi, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 1, Pp 101122- (2023)
Purpose: Local tumor progression is a cause of significant morbidity and mortality in patients with pancreatic ductal adenocarcinoma (PDAC) with surgically unresectable disease. Novel and effective approaches to accomplish durable local control are u
Externí odkaz:
https://doaj.org/article/ee77f111869b4d7c8620b432196590f6
Autor:
Asfar S. Azmi, Anthony F. Shields, Ramzi M. Mohammad, Philip A. Philip, Dipesh Uprety, Hirva Mamdani, Yosef Landesman, Rafic Beydoun, Steve Kim, Mohammed Najeeb Al-Hallak, Yousef Mzannar, Sahar Bannoura, Rachel Sexton, Md. Hafiz Uddin, Amro Aboukameel, Yiwei Li, Misako Nagasaka, Husain Yar Khan
The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718acd53ed3f4593886fb1335899dd3c
https://doi.org/10.1158/2767-9764.c.6550541
https://doi.org/10.1158/2767-9764.c.6550541
Autor:
Asfar S. Azmi, Anthony F. Shields, Ramzi M. Mohammad, Philip A. Philip, Dipesh Uprety, Hirva Mamdani, Yosef Landesman, Rafic Beydoun, Steve Kim, Mohammed Najeeb Al-Hallak, Yousef Mzannar, Sahar Bannoura, Rachel Sexton, Md. Hafiz Uddin, Amro Aboukameel, Yiwei Li, Misako Nagasaka, Husain Yar Khan
Supplementary Figure 1. XPO1-KRAS synthetic lethal interaction identified using the Slorth database. Supplementary Figure 2. KRAS WT, KRAS G12D and KRAS G12V MEF cell lines were refractory to growth inhibition by selinexor or MRTX1257 or their combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b8baa9b3cbc288ae8a6d95ae6fcdd3d
https://doi.org/10.1158/2767-9764.22544132.v1
https://doi.org/10.1158/2767-9764.22544132.v1
Autor:
Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Md. Hafiz Uddin, Sahar Bannoura, Yousef Mzannar, Ibrahim Azar, Eliza Beal, Miguel Tobon, Steve Kim, Rafic Beydoun, Erkan Baloglu, William Senapedis, Bassel El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al-Hallak, Asfar S. Azmi
Publikováno v:
bioRxiv
KRASG12C inhibitors have revolutionized the treatment landscape for cancer patients harboring the G12C mutant isoform of KRAS. With the recent FDA approval of sotorasib and adagrasib, patients now have access to more promising treatment options. Howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf004144758091e6e3046d4c1478a526
https://doi.org/10.1101/2023.03.27.534309
https://doi.org/10.1101/2023.03.27.534309
Autor:
Md. Hafiz Uddin, Amro Aboukameel, Husain Khan, Sahar Bannoura, Yiwei Li, Abhinav Deol, Jay Yang, Asfar Sohail Azmi, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian
Publikováno v:
Blood. 140:8811-8812
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d88532f1dae701eabdfc86db64cd6782
https://doi.org/10.1182/blood-2022-168151
https://doi.org/10.1182/blood-2022-168151
Autor:
Husain Yar Khan, Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton, Sahar Bannoura, Yousef Mzannar, Mohammed Najeeb Al-Hallak, Steve Kim, Rafic Beydoun, Yosef Landesman, Hirva Mamdani, Dipesh Uprety, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi
Publikováno v:
Cancer Res Commun
The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe9c14efed5348f093f2a93a3601a87b
https://pubmed.ncbi.nlm.nih.gov/35573474
https://pubmed.ncbi.nlm.nih.gov/35573474
Autor:
Md. Hafiz Uddin, Amro Aboukameel, Yiwei Li, Husain Yar Khan, Rachel E. Sexton, Sahar Bannoura, Gregory Dyson, Mohammad Najeeb Al-Hallak, Yosef Mzannar, Amr Mohamed, Yosef Landesman, Steve Kim, Rafic Beydoun, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi
The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nab-Paclitaxel (GemPac) treatment indicating the need for more effective combinations for this recalcitrant diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::430553d724fed3aabb909abe76f3d148
https://doi.org/10.1101/2022.03.08.481108
https://doi.org/10.1101/2022.03.08.481108
Autor:
Rachel E. Sexton, Md Hafiz Uddin, Sahar Bannoura, Husain Yar Khan, Yousef Mzannar, Yiwei Li, Amro Aboukameel, Mohammad Najeeb Al-Hallak, Bayan Al-Share, Amr Mohamed, Misako Nagasaka, Bassel El-Rayes, Asfar S. Azmi
Publikováno v:
Cancer metastasis reviewsReferences. 41(2)
Pancreatic cancer is a deadly disease that is increasing in incidence throughout the world. There are no clear causal factors associated with the incidence of pancreatic cancer; however, some correlation to smoking, diabetes and alcohol has been desc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49861fa1b7643c7cd1606c9b76d8690
https://pubmed.ncbi.nlm.nih.gov/35536453
https://pubmed.ncbi.nlm.nih.gov/35536453
Autor:
Mandana Kamgar, Husain Yar Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed Najeeb Al Hallak, Philip Agop Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, William A. Hall
Publikováno v:
Journal of Clinical Oncology. 41:TPS760-TPS760
TPS760 Background: Local tumor progression is a cause of significant mortality and morbidity in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). Effective approaches to achieve durable local control are urgently needed. Metabolic r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0eb7ba4c3044c0eea3749622a96f1c64
https://doi.org/10.1200/jco.2023.41.4_suppl.tps760
https://doi.org/10.1200/jco.2023.41.4_suppl.tps760
Autor:
Md. Hafiz Uddin, Sahar Bannoura, Yiwei Li, Husain Y. Khan, Amro Aboukameel, Mohammed N. Al-Hallak, Rafic Beydoun, Steve Kim, Yosef Landesman, Ramzi M. Mohammad, Anthony Shields, Asfar S. Azmi
Publikováno v:
Cancer Research. 82:5330-5330
Background: The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression after Gemcitabine-nab-Paclitaxel (GemPac) treatment indicating the need for more effective combination therapies for this highly recalcitrant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8383937f1bd5cdf972de4889c2ea324e
https://doi.org/10.1158/1538-7445.am2022-5330
https://doi.org/10.1158/1538-7445.am2022-5330